SAM
RXRX icon

Smartleaf Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Smartleaf Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23K Hold
874
– – ﹤0.01% 2833
2026
Q1 		$2.48K Buy
874
+297
+51% +$1.15K ﹤0.01% 2902
2025
Q4 		$2.37K Buy
577
+406
+237% +$2.01K ﹤0.01% 2936
2025
Q3 		$839 Buy
+171
New +$898 ﹤0.01% 2778
2025
Q1 		– Sell
-269
Closed -$1.82K – 2979
2024
Q4 		$1.82K Hold
269
– – ﹤0.01% 2553
2024
Q3 		$1.88K Buy
269
+249
+1,245% +$1.78K ﹤0.01% 2492
2024
Q2 		$151 Buy
+20
New +$174 ﹤0.01% 2703

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Smartleaf Asset Management's RXRX Position: Q2 2026 in Review

Smartleaf Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 874 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

Smartleaf Asset Management first reported a position in RXRX in Q2 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Smartleaf Asset Management held 874 shares of Recursion Pharmaceuticals worth $3.23K as of Q2 2026.
  • Smartleaf Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2833 holding.
  • Smartleaf Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.